AMLX

#2013
Amylyx Pharmaceuticals, Inc. Common Stock
16.92 USD
+2.73%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
16.92
16.92
Jahresspanne
3.79
17.49
Tagesänderung
+2.73%
Monatliche Änderung
+19.24%
6 month change
+15.89%
Jahresänderung
+332.74%
Vorheriger Schlusskurs
16.47
Eröffnung
16.92
Bid
Ask
Tief
16.92
High
16.92
Volumen
87
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
Gewinn- und Verlustrechnung Bilanz Cashflow
Wert 2022202320242025 TTM

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Nachrichten